Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 StudyMichèle Cavo, Michele Baccarani, Giulia Perrone et al.|Blood|2010Cited by 12
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.Michèle Cavo, Michele Baccarani, Nicoletta Testoni et al.|Blood|2008Cited by 10
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Luca Laurenti, Massimo Gentile et al.|Hematological Oncology|2023Cited by 2
Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic LeukemiaValentina Griggio, Marta Coscia, Candida Vitale et al.|Blood|2024Cited by 1
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)Paola Tacchetti, Michèle Cavo, Carolina Terragna et al.|Blood|2011Cited by 1